Searched for
ACCESS TO HIV MEDICATION
Lenacapavir HIV shot approved in US may enter Canada by 2026; just two injections needed a yearA twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by mid-2026. Develope...
Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug LenacapavirEmcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention a...
Aurobindo, Cipla, Viatris in licensing pact with MPP to make ViiV's HIV preventive therapyThrough the MPP-ViiV Healthcare agreement, the three generic manufacturers will be able to develop, manufacture, and supply generic version...
How India can 'PrEP' better for fight against HIVIndia experienced a surge of HIV cases in the 1990s and early 2000s. According to the National Social Marketing Centre (NSMC), during 2001-...
40 years since the first reported case of AIDS, where's the HIV vaccine?More people now have access to antiretroviral therapy, which keeps down the amount of virus in their body.
With Section 377 out, hopes now for renewed efforts of HIV prevention among high risk groupsOne of the key recommendations that global public health organisations like WHO have have stressed on is preventing AIDS among high risk gr...
Health Ministry implements HIV, AIDS ActThe act seeks to prevent and control the spread of HIV and AIDS and and creates mechanisms for redressing the complaints of persons infecte...
Parliamentary panel asks health ministry to expedite setting up of anti-retroviral treatment centresThe panel has also asked the ministry to devise a mechanism for providing an expanded access to subsidised anti-retroviral therapy for poor...
ART can help HIV positive person live normal lifespan: ExpertAccording to IAPAC guidelines 2015, an estimated 50 per cent of people living with HIV globally are unaware of their status.
Cipla, Aurobindo, Emcure to supply HIV drugs for UN-backed programmeAurobindo Pharma Chief Executive Officer said the new licence would help ensure the timely introduction of generic ATV in developing countr...
Cipla to market MSD's HIV drug 'raltegravir' in IndiaMSD in India Managing Director K G Ananthakrishnan said the partnership is aligned with the company's commitment towards patients in India.
- Concerns over drug prices under FTA raised with EU
The EU leader replied, "Health is our main concern," and received a memorandum from her on the issue which she said was signed by "hundreds...
- US bio-pharma firm Gilead Sciences in pact with four Indian cos
US-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.
- Abbott patent application for HIV drug spurned
Besides I-MAK, a few local HIV drug makers such as Cipla and US-based Mylan-owned Matrix Laboratories had also opposed Abbott's attempt to ...
- India rejects Abbot lab's patent application for HIV drug
India has rejected a drug patent application of a US multi-national pharma company, paving way for easy access to an important life-saving ...
- On an advocacy mission
Michel Sidibe, Executive Director, UNAIDS speaks about what he feels India's role should be going forward.
- HIV drugs to cost more as cos rush for patents
HIV treatment in India could get costlier as global pharma cos have started securing patents for drugs used to treat AIDS and related disea...